Home Cart Sign in  
Chemical Structure| 248281-84-7 Chemical Structure| 248281-84-7

Structure of Laquinimod
CAS No.: 248281-84-7

Chemical Structure| 248281-84-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Laquinimod is an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis.

Synonyms: ABR-215062; LAQ; TV-5600

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Laquinimod

CAS No. :248281-84-7
Formula : C19H17ClN2O3
M.W : 356.80
SMILES Code : C1=CC=C(Cl)C2=C1N(C(=C(C2=O)C(=O)N(CC)C3=CC=CC=C3)O)C
Synonyms :
ABR-215062; LAQ; TV-5600
InChI Key :GKWPCEFFIHSJOE-UHFFFAOYSA-N
Pubchem ID :54677946

Safety of Laquinimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse hepatocytes 0.06 ±0.02μM 4 h To evaluate the induction of Cyp1a1 mRNA by Laquinimod in mouse hepatocytes, showing different effects at different time points Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152.
human hepatocytes 0.2 ±0.04μM 24 h To evaluate the induction of CYP1A1 and CYP1A2 mRNA by Laquinimod in human hepatocytes, showing significant induction Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152.
cerebellar slices 30 μM 2 h To assess the direct effect of laquinimod on glutamatergic transmission in EAE cerebellar slices. Results showed that laquinimod significantly recovered the kinetic alterations of glutamatergic transmission in EAE cerebellum. J Neuroinflammation. 2018 Jan 5;15(1):5.
human NK cells 15 μM 120 h To evaluate the activation effect of Laquinimod on human NK cells, results showed that Laquinimod significantly increased the proportion of CD69+ in both CD56bright and CD56dim human NK cell subsets. J Neuroinflammation. 2019 Feb 26;16(1):49.
NK cells 10 μM 48 h To evaluate the activation effect of Laquinimod on NK cells, results showed that Laquinimod significantly increased the proportion of CD69+ in NK cells. J Neuroinflammation. 2019 Feb 26;16(1):49.
Primary human astrocytes 0, 100 nM, 250 nM, 1 µM, 5 µM 24 h To assess the effect of Laquinimod on astrocytic inflammatory response, results showed that Laquinimod significantly reduced pro-inflammatory factors secretion in astrocytes. Acta Neuropathol. 2012 Sep;124(3):411-24.
Primary mouse microglia 1 µM 20 h To assess the effect of Laquinimod on microglial inflammatory response, results showed that Laquinimod had minor effects on microglial cytokine secretion. Acta Neuropathol. 2012 Sep;124(3):411-24.
Oligodendrocyte precursor cells (OPCs) 0, 0.01, 0.1, 1, 10 µM 48 h To assess the effect of Laquinimod on oligodendroglial survival, results showed that Laquinimod did not affect cell survival. Acta Neuropathol. 2012 Sep;124(3):411-24.
CD14+ monocytes 10 μM and 100 μM 30 min To evaluate the effect of Laquinimod on the NF-κB signaling pathway, results showed that Laquinimod inhibited phosphorylation of the NF-κB p65 subunit. Neurol Neuroimmunol Neuroinflamm. 2020 Nov 17;8(1):e908.
CD14+ monocytes 10 μM and 100 μM 24 h To evaluate the effect of Laquinimod on monocyte survival and proliferation, results showed that Laquinimod did not affect monocyte survival and proliferation. Neurol Neuroimmunol Neuroinflamm. 2020 Nov 17;8(1):e908.
primary mouse astrocytes 250 nM 2 h To evaluate the effect of Laquinimod on NF-κB activation in astrocytes. Results showed that Laquinimod pretreatment significantly reduced NF-κB activation after cytokine stimulation. Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(3):e233.
Primary astrocytes 100 ng/mL 24 h To evaluate the effects of Delaq (a metabolite of Laquinimod) on AHR activation in astrocytes. Results showed Delaq, but not Laquinimod itself, induced expression of the AHR-responsive gene Cyp1b1 and reduced production of proinflammatory mediators (e.g., Ccl2, Nos2, Tnfa) while enhancing anti-inflammatory Il10 expression. Neurol Neuroimmunol Neuroinflamm. 2021 Jan 6;8(2):e946.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Multiple myeloma (MM)-burdened mouse model Oral gavage 25 mg/kg Once daily for 2 weeks To evaluate the therapeutic effect of Laquinimod on BRONJ-like lesions, results showed that Laquinimod significantly decreased the M1/M2 macrophage ratio and concomitantly suppressed the incidence of BRONJ-like conditions in mice. Clin Cancer Res. 2013 Jun 15;19(12):3176-88
Mice Experimental autoimmune encephalomyelitis (EAE) Oral 25 mg/kg Once daily for 30 days To evaluate the therapeutic effect of Laquinimod in the EAE model, showing significant inhibition of disease progression via AhR activation Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152.
C57BL/6N mice Experimental autoimmune encephalomyelitis (EAE) Continuous intracerebroventricular (icv) infusion 1.25 mg/kg Once daily for 4 weeks To evaluate the direct neuroprotective effect of laquinimod on motor disability in EAE mice. Results showed that laquinimod significantly ameliorated motor disability in the late stage of EAE but had no remarkable effects on inflammatory markers. J Neuroinflammation. 2018 Jan 5;15(1):5.
Mice Experimental autoimmune encephalomyelitis (EAE) Oral gavage 25 mg/kg Daily for 11 days To evaluate the therapeutic effect of Laquinimod on EAE, results showed that Laquinimod improved EAE symptoms by activating NK cells and reducing CD11chighMHCII+ dendritic cells. J Neuroinflammation. 2019 Feb 26;16(1):49.
Mice Moderate TBI induced by fluid percussion Oral gavage 25 mg/kg Once daily, 7 days before TBI and 3 days after TBI Laquinimod reduced monocyte infiltration into the brain, decreased axonal damage, restored neurogenesis, and prevented long-term lateral ventricle enlargement caused by TBI. J Neuroinflammation. 2018 Jan 30;15(1):26
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) model Oral 1, 5, or 25 mg/kg Once daily, starting the day post-immunization, for 30 days To investigate the protective effects of laquinimod on the optic nerve and retina in an EAE model. Results showed that laquinimod reduced neurological symptoms, improved retinal ganglion cell survival, and decreased demyelination and inflammatory cell infiltration in the optic nerve. J Neuroinflammation. 2018 Jun 14;15(1):183
C57BL/6J mice and Rag1-/- mice Cuprizone-induced demyelination model Oral 5 mg/kg and 25 mg/kg Daily administration for 1 or 6 weeks To assess the protective effect of Laquinimod on cuprizone-induced demyelination, results showed that Laquinimod significantly reduced demyelination, microglial activation, axonal damage and reactive gliosis. Acta Neuropathol. 2012 Sep;124(3):411-24.
Mice Cuprizone-induced demyelination model Oral gavage 25 mg/kg Once daily for 6 weeks To assess the protective effect of Laquinimod in the cuprizone-induced demyelination model. Results showed that Laquinimod significantly reduced demyelination, oligodendrocyte loss, microglial infiltration, and acute axonal damage. Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(3):e233.
C57Bl/6 mice Experimental autoimmune encephalomyelitis (EAE) model Oral gavage 25 mg/kg Daily administration starting from day 2 post-induction To investigate the therapeutic effects of Laquinimod via AHR activation in astrocytes in the EAE model. Results demonstrated Laquinimod ameliorated clinical symptoms, reduced CNS infiltration of inflammatory monocytes and effector T cells, and suppressed proinflammatory pathways (e.g., NF-κB signaling) in astrocytes via transcriptomic analysis. Neurol Neuroimmunol Neuroinflamm. 2021 Jan 6;8(2):e946.
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) Oral 25 mg/kg Daily, starting from the day of immunization To evaluate the influence of oral laquinimod on induction of T follicular helper cells, development of meningeal B cell aggregates, and clinical disease in a spontaneous B cell–dependent MS model. Results showed that laquinimod treatment reduced CD11c+CD4+dendritic cells, inhibited expansion of PD-1+CXCR5+BCL6+T follicular helper and IL-21–producing activated CD4+CD44+T cells, suppressed B cell CD40 expression, diminished formation of Fas+GL7+germinal center B cells, and inhibited development of MOG-specific IgG. Laquinimod not only prevented rMOG-induced EAE but also inhibited development of spontaneous EAE and the formation of meningeal B cell aggregates. Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01404117 Relapsing Multiple Sclerosis Phase 2 Withdrawn(Study is being redes... More >>igned) Less << January 2014 -
NCT00605215 Multiple Sclerosis Phase 3 Completed - -
NCT01707992 Multiple Sclerosis Phase 3 Completed - -
NCT00349193 Relapsing Remitting Multiple S... More >>clerosis Less << Phase 2 Completed - -
NCT00745615 Relapsing Remitting Multiple S... More >>clerosis Less << Phase 2 Terminated(Sponsor terminated ... More >>RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.) Less << - -
NCT01975298 Relapsing Remitting Multiple S... More >>clerosis Less << Phase 3 Withdrawn(Business Decision) - -
NCT00988052 Relapsing Multiple Sclerosis PHASE3 TERMINATED 2017-07-01 Teva Investigational Site 1076... More >>, Phoenix, Arizona, 85004, United States|Teva Investigational Site 1090, Centennial, Colorado, 80112, United States|Teva Investigational Site 1088, Fort Collins, Colorado, 80528, United States|Teva Investigational Site 1102, Northbrook, Illinois, 60062, United States|Teva Investigational Site 1081, Fort Wayne, Indiana, 46845, United States|Teva Investigational Site 1083, Des Moines, Iowa, 50314, United States|Teva Investigational Site 1086, Kansas City, Kansas, 66103, United States|Teva Investigational Site 1101, Lexington, Kentucky, 40513, United States|Teva Investigational Site 1096, Farmington Hills, Michigan, 48334, United States|Teva Investigational Site 1093, Minneapolis, Minnesota, 55414, United States|Teva Investigational Site 1098, Saint Louis, Missouri, 63104, United States|Teva Investigational Site 1082, New York, New York, 10016, United States|Teva Investigational Site 1073, Winston-Salem, North Carolina, 27157, United States|Teva Investigational Site 1097, Fargo, North Dakota, 58103, United States|Teva Investigational Site 1084, Dayton, Ohio, 45417, United States|Teva Investigational Site 1092, Oklahoma City, Oklahoma, 73120, United States|Teva Investigational Site 1100, Hershey, Pennsylvania, 17033-0850, United States|Teva Investigational Site 1075, Lubbock, Texas, 79410, United States|Teva Investigational Site 1078, San Antonio, Texas, 78231, United States|Teva Investigational Site 1085, Milwaukee, Wisconsin, 53215, United States|Teva Investigational Site 3300, Klagenfurt, 9020, Austria|Teva Investigational Site 3303, Linz, A-4021, Austria|Teva Investigational Site 3302, Sankt Polten, 3100, Austria|Teva Investigational Site 5901, Pleven, 5800, Bulgaria|Teva Investigational Site 5904, Sofia, 1113, Bulgaria|Teva Investigational Site 5903, Sofia, 1309, Bulgaria|Teva Investigational Site 5900, Sofia, 1606, Bulgaria|Teva Investigational Site 5905, Sofia, 1606, Bulgaria|Teva Investigational Site 5902, Varna, 9010, Bulgaria|Teva Investigational Site 1132, Bedford, Nova Scotia, B4A 1A9, Canada|Teva Investigational Site 1126, London, Ontario, N6A 5A5, Canada|Teva Investigational Site 1128, Ottawa, Ontario, K2G 6E2, Canada|Teva Investigational Site 1134, Toronto, Ontario, M4N 3M5, Canada|Teva Investigational Site 1130, Greenfield Park, Quebec, J4V 2J2, Canada|Teva Investigational Site 1129, Montreal, Quebec, H1T 2M4, Canada|Teva Investigational Site 1131, Sherbrooke, Quebec, J1H 5N4, Canada|Teva Investigational Site 5417, Olomouc, 779 00, Czechia|Teva Investigational Site 5416, Ostrava - poruba, 708 52, Czechia|Teva Investigational Site 5504, Tallinn, EE-10617, Estonia|Teva Investigational Site 5505, Tartu, EE-51014, Estonia|Teva Investigational Site 3525, Besancon, 25030, France|Teva Investigational Site 3527, Bron Cedex, 69677, France|Teva Investigational Site 3526, Clermont-Ferrand Cedex 1, 63003, France|Teva Investigational Site 3524, Lille Cedex, 59037, France|Teva Investigational Site 3528, Marseille Cedex 5, 13385, France|Teva Investigational Site 3529, Rennes Cedex 9, 35033, France|Teva Investigational Site 8100, Tbilisi, 0112, Georgia|Teva Investigational Site 8101, Tbilisi, 0179, Georgia|Teva Investigational Site 3247, Bayreuth, 95445, Germany|Teva Investigational Site 3241, Berlin, 10713, Germany|Teva Investigational Site 3238, Berlin, 13347, Germany|Teva Investigational Site 3248, Bochum, 44791, Germany|Teva Investigational Site 3245, Dresden, 01307, Germany|Teva Investigational Site 3237, Emden, 26721, Germany|Teva Investigational Site 3242, Erbach, 64711, Germany|Teva Investigational Site 3240, Erfurt, 99089, Germany|Teva Investigational Site 3249, Freiburg, 79106, Germany|Teva Investigational Site 3236, Hamburg, 20246, Germany|Teva Investigational Site 3246, Hamburg, 22417, Germany|Teva Investigational Site 3239, Hannover, 30171, Germany|Teva Investigational Site 3243, Heidelberg, 69120, Germany|Teva Investigational Site 3251, Munster, 48149, Germany|Teva Investigational Site 3250, Trier, 54292, Germany|Teva Investigational Site 3244, Ulm, 89081, Germany|Teva Investigational Site 5115, Budapest, H-1145, Hungary|Teva Investigational Site 5114, Debrecen, 4043, Hungary|Teva Investigational Site 5116, Miskolc, 3526, Hungary|Teva Investigational Site 5117, Veszprem, H-8200, Hungary|Teva Investigational Site 8031, Haifa, 3436212, Israel|Teva Investigational Site 8030, Jerusalem, 9112001, Israel|Teva Investigational Site 8033, Ramat Gan, 5262160, Israel|Teva Investigational Site 8032, Tel Aviv, 78278, Israel|Teva Investigational Site 3044, Catania, 95124, Italy|Teva Investigational Site 3045, Fidenza, 43036, Italy|Teva Investigational Site 3042, Gallarate, 21013, Italy|Teva Investigational Site 3046, Grosseto, 58100, Italy|Teva Investigational Site 3038, Milano, 20132, Italy|Teva Investigational Site 555, Milano, 20132, Italy|Teva Investigational Site 3039, Milano, 20148, Italy|Teva Investigational Site 3041, Palermo, 90146, Italy|Teva Investigational Site 3040, Rome, 00133, Italy|Teva Investigational Site 5704, Kaunas, 50009, Lithuania|Teva Investigational Site 5705, Siauliai, 76231, Lithuania|Teva Investigational Site 3810, Nieuwegein, 3430 EM, Netherlands|Teva Investigational Site 3809, Nijmegen, 6525 GC, Netherlands|Teva Investigational Site 5322, Czestochowa, 42-280, Poland|Teva Investigational Site 5320, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5316, Katowice, 40-752, Poland|Teva Investigational Site 5318, Kielce, 25-726, Poland|Teva Investigational Site 5319, Konskie, 26-200, Poland|Teva Investigational Site 5317, Krakow, 31-826, Poland|Teva Investigational Site 5315, Lodz, 90-153, Poland|Teva Investigational Site 5325, Warszawa, 04-749, Poland|Teva Investigational Site 5208, Bucharest, 011461, Romania|Teva Investigational Site 5210, Cluj-Napoca, 400437, Romania|Teva Investigational Site 5212, Constanta, 900123, Romania|Teva Investigational Site 5211, Targu-Mures, 540136, Romania|Teva Investigational Site 5209, Timisoara, 300736, Romania|Teva Investigational Site 5029, Ekaterinburg, 620102, Russian Federation|Teva Investigational Site 5021, Moscow, 127015, Russian Federation|Teva Investigational Site 5028, Nizhny Novgorod, 603126, Russian Federation|Teva Investigational Site 5027, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5030, Perm, 614990, Russian Federation|Teva Investigational Site 5022, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5025, St. Petersburg, 194044, Russian Federation|Teva Investigational Site 5024, St. Petersburg, 194354, Russian Federation|Teva Investigational Site 5023, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5026, St.Petersburg, 191186, Russian Federation|Teva Investigational Site 6100, Belgrade, 11000, Serbia|Teva Investigational Site 6102, Nis, 18 000, Serbia|Teva Investigational Site 3132, Barcelona, 08035, Spain|Teva Investigational Site 3134, Barcelona, 08036, Spain|Teva Investigational Site 3144, Barcelona, 08041, Spain|Teva Investigational Site 3140, Beade-Pontevedra, 36312, Spain|Teva Investigational Site 3142, Getafe, 28905, Spain|Teva Investigational Site 3135, Lleida, 25198, Spain|Teva Investigational Site 3133, Madrid, 28040, Spain|Teva Investigational Site 3146, Madrid, 28046, Spain|Teva Investigational Site 3137, Murcia, 30120, Spain|Teva Investigational Site 3138, Pontevedra, 36001, Spain|Teva Investigational Site 3136, Salt, 17190, Spain|Teva Investigational Site 3139, Santiago de Compostela, 15706, Spain|Teva Investigational Site 3143, Valencia, 46010, Spain|Teva Investigational Site 4204, Stockholm, 14186, Sweden|Teva Investigational Site 4205, Stockholm, 17176, Sweden|Teva Investigational Site 4206, Stockholm, 18288, Sweden|Teva Investigational Site 8201, Izmir, 35340, Turkey|Teva Investigational Site 5803, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5802, Kyiv, 03110, Ukraine|Teva Investigational Site 5804, Kyiv, 03115, Ukraine|Teva Investigational Site 5800, Lviv, 79010, Ukraine|Teva Investigational Site 5801, Vinnytsya, 21005, Ukraine|Teva Investigational Site 3425, Liverpool, L9 7LJ, United Kingdom|Teva Investigational Site 3424, London, E1 2AT, United Kingdom|Teva Investigational Site 3422, Sheffield, S10 2JF, United Kingdom Less <<
NCT01085097 Lupus Nephritis Phase 2 Completed - -
NCT00737932 Crohn's Disease Phase 2 Completed - -
NCT00509145 Multiple Sclerosis Phase 3 Completed - -
NCT01085084 Lupus Arthritis Phase 2 Completed - United States, Alabama ... More >> Teva Investigational Site 1363 Birmingham, Alabama, United States United States, California Teva Investigational Site 1359 Los Angeles, California, United States Teva Investigational Site 1352 San Francisco, California, United States Teva Investigational Site 1365 San Leandro, California, United States Teva Investigational Site 1368 West Hollywood, California, United States United States, Illinois Teva Investigational Site 1367 Chicago, Illinois, United States United States, Maryland Teva Investigational Site 1370 Baltimore, Maryland, United States Teva Investigational Site 1362 Cumberland, Maryland, United States Teva Investigational Site 1360 Hagerstown, Maryland, United States United States, New York Teva Investigational Site 1369 Bronx, New York, United States Teva Investigational Site 1353 Manhasset, New York, United States Teva Investigational Site 1355 New York, New York, United States United States, North Carolina Teva Investigational Site 1356 Charlotte, North Carolina, United States United States, Ohio Teva Investigational Site 1354 Columbus, Ohio, United States United States, South Carolina Teva Investigational Site 1366 Charleston, South Carolina, United States Canada, Alberta Teva Investigational Site 1139 Edmonton, Alberta, Canada Canada, Ontario Teva Investigational Site 1136 London, Ontario, Canada Teva Investigational Site 1137 Toronto, Ontario, Canada Canada, Quebec Teva Investigational Site 1142 Montreal, Quebec, Canada Less <<
NCT02215616 Huntington's Disease Phase 2 Completed - -
NCT02284568 Primary Progressive Multiple S... More >>clerosis Less << Phase 2 Completed - -
NCT01047319 Relapsing Multiple Sclerosis PHASE3 TERMINATED 2017-06-30 Teva Investigational Site 1267... More >>, Homewood, Alabama, 35209, United States|Teva Investigational Site 1237, Phoenix, Arizona, 85013, United States|Teva Investigational Site 1279, Phoenix, Arizona, 85018, United States|Teva Investigational Site 1276, Tucson, Arizona, 85704, United States|Teva Investigational Site 1272, Pasadena, California, 91105, United States|Teva Investigational Site 1238, Sacramento, California, 95817, United States|Teva Investigational Site 1280, Aurora, Colorado, 80045, United States|Teva Investigational Site 1282, Sarasota, Florida, 34233, United States|Teva Investigational Site 1275, Atlanta, Georgia, 30309, United States|Teva Investigational Site 1250, Peoria, Illinois, 61603, United States|Teva Investigational Site 1260, Indianapolis, Indiana, 46202, United States|Teva Investigational Site 1263, Shreveport, Louisiana, 71103, United States|Teva Investigational Site 1269, Baltimore, Maryland, 21201, United States|Teva Investigational Site 1273, Albany, New York, 12205, United States|Teva Investigational Site 1264, Amherst, New York, 14226, United States|Teva Investigational Site 1261, Akron, Ohio, 44320, United States|Teva Investigational Site 1245, Cleveland, Ohio, 44195-5244, United States|Teva Investigational Site 1247, Columbus, Ohio, 43221, United States|Teva Investigational Site 1244, Portland, Oregon, 97225, United States|Teva Investigational Site 1281, Nashville, Tennessee, 37205, United States|Teva Investigational Site 1270, Roanoke, Virginia, 24018, United States|Teva Investigational Site 1253, Tacoma, Washington, 98405, United States|Teva Investigational Site 5914, Pleven, 5800, Bulgaria|Teva Investigational Site 5915, Pleven, 5800, Bulgaria|Teva Investigational Site 5917, Plovdiv, 4000, Bulgaria|Teva Investigational Site 4212, Ruse, 7000, Bulgaria|Teva Investigational Site 5916, Shumen, 9700, Bulgaria|Teva Investigational Site 5920, Sofia, 1000, Bulgaria|Teva Investigational Site 5907, Sofia, 1113, Bulgaria|Teva Investigational Site 5910, Sofia, 1113, Bulgaria|Teva Investigational Site 5909, Sofia, 1309, Bulgaria|Teva Investigational Site 5919, Sofia, 1407, Bulgaria|Teva Investigational Site 5906, Sofia, 1606, Bulgaria|Teva Investigational Site 5908, Sofia, 1606, Bulgaria|Teva Investigational Site 5911, Sofia, 1606, Bulgaria|Teva Investigational Site 5912, Sofia, 1606, Bulgaria|Teva Investigational Site 5918, Stara Zagora, 6000, Bulgaria|Teva Investigational Site 5913, Varna, 9010, Bulgaria|Teva Investigational Site 4211, Veliko Tarnovo, 5000, Bulgaria|Teva Investigational Site 6003, Osijek, 31 000, Croatia|Teva Investigational Site 6005, Varazdin, 42000, Croatia|Teva Investigational Site 6001, Zagreb, 10000, Croatia|Teva Investigational Site 6002, Zagreb, 10000, Croatia|Teva Investigational Site 6006, Zagreb, 10000, Croatia|Teva Investigational Site 5419, Olomouc, 779 00, Czechia|Teva Investigational Site 5418, Praha 2, 128 08, Czechia|Teva Investigational Site 5420, Praha 5- Motol, 150 06, Czechia|Teva Investigational Site 5421, Teplice, 415 29, Czechia|Teva Investigational Site 5508, Kohtla-Jarve, 31025, Estonia|Teva Investigational Site 5507, Tallinn, EE-10617, Estonia|Teva Investigational Site 5509, Tartu, EE-51014, Estonia|Teva Investigational Site 8102, Tbilisi, 0112, Georgia|Teva Investigational Site 8104, Tbilisi, 0112, Georgia|Teva Investigational Site 8103, Tbilisi, 0179, Georgia|Teva Investigational Site 6703, Berlin, 10117, Germany|Teva Investigational Site 6402, Berlin, 12203, Germany|Teva Investigational Site 6400, Ulm, 89081, Germany|Teva Investigational Site 8041, Jerusalem, 9112001, Israel|Teva Investigational Site 8040, Ramat Gan, 5262160, Israel|Teva Investigational Site 3056, Bologna, 40139, Italy|Teva Investigational Site 3053, Cefalu, 90015, Italy|Teva Investigational Site 3054, Chieti, 66100, Italy|Teva Investigational Site 3061, Empoli, 50053, Italy|Teva Investigational Site 3049, Firenze, 50139, Italy|Teva Investigational Site 3055, Napoli, 80131, Italy|Teva Investigational Site 3048, Rome, 00133, Italy|Teva Investigational Site 3052, Rome, 00149, Italy|Teva Investigational Site 3050, Rome, 00168, Italy|Teva Investigational Site 5708, Kaunas, 50009, Lithuania|Teva Investigational Site 5707, Siauliai, 76231, Lithuania|Teva Investigational Site 6500, Skopje, 1000, North Macedonia|Teva Investigational Site 6501, Skopje, 1000, North Macedonia|Teva Investigational Site 6502, Skopje, 1000, North Macedonia|Teva Investigational Site 5337, Bialystok, 15-402, Poland|Teva Investigational Site 5329, Gdansk, 80-803, Poland|Teva Investigational Site 5338, Gdansk, 80-952, Poland|Teva Investigational Site 6602, Gorzow Wielkopolski, 66-400, Poland|Teva Investigational Site 5333, Grodzisk Mazowiecki, 05-825, Poland|Teva Investigational Site 5334, Katowice, 40-650, Poland|Teva Investigational Site 5339, Katowice, 40-684, Poland|Teva Investigational Site 6603, Kielce, 25-726, Poland|Teva Investigational Site 4213, Konskie, 26-200, Poland|Teva Investigational Site 5332, Koscierzyna, 83-400, Poland|Teva Investigational Site 5345, Krakow, 31-826, Poland|Teva Investigational Site 5328, Lodz, 90-153, Poland|Teva Investigational Site 5330, Olsztyn, 10-560, Poland|Teva Investigational Site 5331, Szczecin, 70-111, Poland|Teva Investigational Site 5336, Warsaw, 02-957, Poland|Teva Investigational Site 5340, Warszawa, 00-909, Poland|Teva Investigational Site 5341, Warszawa, 02-097, Poland|Teva Investigational Site 5335, Wroclaw, 50-556, Poland|Teva Investigational Site 5235, Balotesti, 077015, Romania|Teva Investigational Site 5218, Bucharest, 010825, Romania|Teva Investigational Site 5214, Bucuresti, 022328, Romania|Teva Investigational Site 5213, Bucuresti, 050098, Romania|Teva Investigational Site 5215, Cluj-Napoca, 400012, Romania|Teva Investigational Site 5217, Constanta, 900591, Romania|Teva Investigational Site 8209, Craiova, 200515, Romania|Teva Investigational Site 5216, Iasi, 700661, Romania|Teva Investigational Site 5219, Sibiu, 550245, Romania|Teva Investigational Site 5043, Barnaul, 656024, Russian Federation|Teva Investigational Site 5033, Moscow, 117152, Russian Federation|Teva Investigational Site 5041, Moscow, 125367, Russian Federation|Teva Investigational Site 5032, Moscow, 127015, Russian Federation|Teva Investigational Site 5038, Novosibirsk, 630087, Russian Federation|Teva Investigational Site 5042, Novosibirsk, 630117, Russian Federation|Teva Investigational Site 5035, Saint Petersburg, 197022, Russian Federation|Teva Investigational Site 5037, Samara, 443095, Russian Federation|Teva Investigational Site 5036, St. Petersburg, 194291, Russian Federation|Teva Investigational Site 5034, St. Petersburg, 197376, Russian Federation|Teva Investigational Site 5044, Ufa, 450007, Russian Federation|Teva Investigational Site 6200, Bratislava, 813 69, Slovakia|Teva Investigational Site 6201, Bratislava, 826 06, Slovakia|Teva Investigational Site 6202, Nitra, 949 01, Slovakia|Teva Investigational Site 6203, Zilina, 010 01, Slovakia|Teva Investigational Site 9007, Bloemfontein, 9301, South Africa|Teva Investigational Site 9001, Cape Town, 7925, South Africa|Teva Investigational Site 9004, Johannesburg, 2157, South Africa|Teva Investigational Site 9003, Parktown- Johannesburg, 2193, South Africa|Teva Investigational Site 9008, Pietermaritzburg, 3201, South Africa|Teva Investigational Site 9005, Pretoria, 0041, South Africa|Teva Investigational Site 9006, Rosebank, 2196, South Africa|Teva Investigational Site 3147, Barcelona, 08035, Spain|Teva Investigational Site 3154, Figueres-Girona, 17600, Spain|Teva Investigational Site 3149, L'Hospitalet de Llobregat, 08907, Spain|Teva Investigational Site 3152, Madrid, 28041, Spain|Teva Investigational Site 3151, Malaga, 29010, Spain|Teva Investigational Site 3148, Sevilla, 41009, Spain|Teva Investigational Site 3153, Tortosa-Tarragona, 43500, Spain|Teva Investigational Site 6503, Chernihiv, 14029, Ukraine|Teva Investigational Site 5823, Chernivtsi, 58018, Ukraine|Teva Investigational Site 5811, Dnipropetrovsk, 49027, Ukraine|Teva Investigational Site 5812, Donetsk, 83003, Ukraine|Teva Investigational Site 5814, Ivano-Frankivsk, 76008, Ukraine|Teva Investigational Site 5817, Kharkiv, 61018, Ukraine|Teva Investigational Site 5818, Kharkiv, 61068, Ukraine|Teva Investigational Site 5815, Kharkiv, 61103, Ukraine|Teva Investigational Site 5822, Kyiv, 03110, Ukraine|Teva Investigational Site 5809, Lviv, 79010, Ukraine|Teva Investigational Site 5820, Odessa, 65025, Ukraine|Teva Investigational Site 5821, Poltava, 36024, Ukraine|Teva Investigational Site 5810, Vinnytsya, 21005, Ukraine|Teva Investigational Site 5819, Zaporizhzhya, 69035, Ukraine|Teva Investigational Site 5816, Zaporizhzhya, 69600, Ukraine Less <<
NCT02085863 Pharmacokinetics ... More >> Pharmacodynamics Less << Phase 1 Completed - Germany ... More >> Teva Investigational Site 32415 Moenchengladbach, Germany Less <<
NCT02284568 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.80mL

0.56mL

0.28mL

14.01mL

2.80mL

1.40mL

28.03mL

5.61mL

2.80mL

References

 

Historical Records

Categories